Listed

Biomerica Inc

BMRANasdaqCIK 73290HealthcareFiscal year ends May 31

Latest reported revenue, Q1 FY2027$1.3mRevenue, Q1 FY2027, three months to 2026-08-31$1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figureThree months to Aug 31, 2026, from the 10-Q filed Oct 15, 2026.

Latest quarter: Q1 FY2027

Three months to Aug 31, 2026, against the same quarter a year earlier.

  • Revenue$1.3mRevenue, Q1 FY2027, three months to 2026-08-31$1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figure−8.3% on a year earlier
  • Gross margin8.1%Gross margin, Q1 FY2027, three months to 2026-08-31. gross profit / revenueGross profit: $103.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Revenue: $1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figure−22.6 pts on a year earlier
  • Operating margin−97.0%Operating margin, Q1 FY2027, three months to 2026-08-31. operating income / revenueOperating income: −$1.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Revenue: $1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figure−16.0 pts on a year earlier
  • Net margin−97.4%Net margin, Q1 FY2027, three months to 2026-08-31. net income / revenueNet income: −$1.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Revenue: $1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figure−97.5 pts on a year earlier
  • Diluted EPS−$0.37Diluted EPS, Q1 FY2027, three months to 2026-08-31−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figureSign changed from a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$1.3mGross margin 8.1%
Diluted EPS−$0.37, Q1 FY2027
Biomerica Inc, key figures for the last eight quarters
Line itemUnitQ2 FY20252024-11-30Q3 FY20252025-02-28Q4 FY20252025-05-31Q1 FY20262025-08-31Q2 FY20262025-11-30Q3 FY20262026-02-28Q4 FY20262026-05-31Q1 FY20272026-08-31Shape over the periods
Revenue$k1,636Revenue, Q2 FY2025, three months to 2024-11-30$1.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-01-14, accession 0001493152-26-002286.Report this figure1,119Revenue, Q3 FY2025, three months to 2025-02-28$1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Report this figure749Revenue, Q4 FY2025, three months to 2025-05-31$749.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851. Derived: 12-month figure less the 9-month figure.Report this figure1,380Revenue, Q1 FY2026, three months to 2025-08-31$1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figure1,210Revenue, Q2 FY2026, three months to 2025-11-30$1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-01-14, accession 0001493152-26-002286.Report this figure987Revenue, Q3 FY2026, three months to 2026-02-28$987.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Report this figure875Revenue, Q4 FY2026, three months to 2026-05-31$875.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851. Derived: 12-month figure less the 9-month figure.Report this figure1,265Revenue, Q1 FY2027, three months to 2026-08-31$1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figure
Gross margin%26.7%Gross margin, Q2 FY2025, three months to 2024-11-30. gross profit / revenueGross profit: $437.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-01-14, accession 0001493152-26-002286.Revenue: $1.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-01-14, accession 0001493152-26-002286.Report this figure1.7%Gross margin, Q3 FY2025, three months to 2025-02-28. gross profit / revenueGross profit: $19.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Revenue: $1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Report this figure(32.6%)Gross margin, Q4 FY2025, three months to 2025-05-31. gross profit / revenueGross profit: −$244.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-08-31, accession 0001493152-26-040851. Derived: 12-month figure less the 9-month figure.Revenue: $749.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851. Derived: 12-month figure less the 9-month figure.Report this figure30.7%Gross margin, Q1 FY2026, three months to 2025-08-31. gross profit / revenueGross profit: $424.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figure4.2%Gross margin, Q2 FY2026, three months to 2025-11-30. gross profit / revenueGross profit: $51.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-01-14, accession 0001493152-26-002286.Revenue: $1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-01-14, accession 0001493152-26-002286.Report this figure(4.5%)Gross margin, Q3 FY2026, three months to 2026-02-28. gross profit / revenueGross profit: −$44.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Revenue: $987.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Report this figure(8.1%)Gross margin, Q4 FY2026, three months to 2026-05-31. gross profit / revenueGross profit: −$71.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-08-31, accession 0001493152-26-040851. Derived: 12-month figure less the 9-month figure.Revenue: $875.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851. Derived: 12-month figure less the 9-month figure.Report this figure8.1%Gross margin, Q1 FY2027, three months to 2026-08-31. gross profit / revenueGross profit: $103.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Revenue: $1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figure
Operating margin%(60.7%)Operating margin, Q2 FY2025, three months to 2024-11-30. operating income / revenueOperating income: −$993.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-01-14, accession 0001493152-26-002286.Revenue: $1.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-01-14, accession 0001493152-26-002286.Report this figure(108.1%)Operating margin, Q3 FY2025, three months to 2025-02-28. operating income / revenueOperating income: −$1.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Revenue: $1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Report this figure(208.8%)Operating margin, Q4 FY2025, three months to 2025-05-31. operating income / revenueOperating income: −$1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-08-31, accession 0001493152-26-040851. Derived: 12-month figure less the 9-month figure.Revenue: $749.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851. Derived: 12-month figure less the 9-month figure.Report this figure(81.0%)Operating margin, Q1 FY2026, three months to 2025-08-31. operating income / revenueOperating income: −$1.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figure(113.5%)Operating margin, Q2 FY2026, three months to 2025-11-30. operating income / revenueOperating income: −$1.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-01-14, accession 0001493152-26-002286.Revenue: $1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-01-14, accession 0001493152-26-002286.Report this figure(131.5%)Operating margin, Q3 FY2026, three months to 2026-02-28. operating income / revenueOperating income: −$1.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Revenue: $987.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Report this figure(175.2%)Operating margin, Q4 FY2026, three months to 2026-05-31. operating income / revenueOperating income: −$1.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-08-31, accession 0001493152-26-040851. Derived: 12-month figure less the 9-month figure.Revenue: $875.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851. Derived: 12-month figure less the 9-month figure.Report this figure(97.0%)Operating margin, Q1 FY2027, three months to 2026-08-31. operating income / revenueOperating income: −$1.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Revenue: $1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figure
Net margin%(58.1%)Net margin, Q2 FY2025, three months to 2024-11-30. net income / revenueNet income: −$950.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Revenue: $1.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-01-14, accession 0001493152-26-002286.Report this figure(103.9%)Net margin, Q3 FY2025, three months to 2025-02-28. net income / revenueNet income: −$1.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Revenue: $1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Report this figure(206.1%)Net margin, Q4 FY2025, three months to 2025-05-31. net income / revenueNet income: −$1.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-08-31, accession 0001493152-26-040851. Derived: 12-month figure less the 9-month figure.Revenue: $749.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851. Derived: 12-month figure less the 9-month figure.Report this figure0.1%Net margin, Q1 FY2026, three months to 2025-08-31. net income / revenueNet income: $2.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figure(109.1%)Net margin, Q2 FY2026, three months to 2025-11-30. net income / revenueNet income: −$1.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Revenue: $1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-01-14, accession 0001493152-26-002286.Report this figure(132.9%)Net margin, Q3 FY2026, three months to 2026-02-28. net income / revenueNet income: −$1.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Revenue: $987.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Report this figure(130.9%)Net margin, Q4 FY2026, three months to 2026-05-31. net income / revenueNet income: −$1.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-08-31, accession 0001493152-26-040851. Derived: 12-month figure less the 9-month figure.Revenue: $875.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851. Derived: 12-month figure less the 9-month figure.Report this figure(97.4%)Net margin, Q1 FY2027, three months to 2026-08-31. net income / revenueNet income: −$1.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Revenue: $1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figure
Diluted EPS$ per share(0.06)Diluted EPS, Q2 FY2025, three months to 2024-11-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-01-14, accession 0001493152-26-002286.Report this figure(0.48)Diluted EPS, Q3 FY2025, three months to 2025-02-28−$0.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Report this figurenot reported (Diluted EPS not reported)0.00Diluted EPS, Q1 FY2026, three months to 2025-08-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figure(0.45)Diluted EPS, Q2 FY2026, three months to 2025-11-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-01-14, accession 0001493152-26-002286.Report this figure(0.44)Diluted EPS, Q3 FY2026, three months to 2026-02-28−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-13, accession 0001493152-26-016388.Report this figurenot reported (Diluted EPS not reported)(0.37)Diluted EPS, Q1 FY2027, three months to 2026-08-31−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-15, accession 0001493152-26-047271.Report this figure
Free cash flow$knot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$4.5mGross margin 8.1%
Diluted EPS−$1.30, FY2026
Free cash flow−$5.4m, FY2024
Biomerica Inc, key figures for the last five fiscal years
Line itemUnitFY20222022-05-31FY20232023-05-31FY20242024-05-31FY20252025-05-31FY20262026-05-31Shape over the periods
Revenue$m18.9Revenue, FY2022, twelve months to 2022-05-31$18.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-08-25, accession 0001493152-23-030254.Report this figure5.3Revenue, FY2023, twelve months to 2023-05-31$5.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-08-28, accession 0001493152-24-034208.Report this figure5.4Revenue, FY2024, twelve months to 2024-05-31$5.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-08-29, accession 0001641172-25-026041.Report this figure5.3Revenue, FY2025, twelve months to 2025-05-31$5.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851.Report this figure4.5Revenue, FY2026, twelve months to 2026-05-31$4.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851.Report this figure
Gross margin%15.8%Gross margin, FY2022, twelve months to 2022-05-31. gross profit / revenueGross profit: $3.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2023-08-25, accession 0001493152-23-030254.Revenue: $18.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-08-25, accession 0001493152-23-030254.Report this figure8.4%Gross margin, FY2023, twelve months to 2023-05-31. gross profit / revenueGross profit: $446.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-08-28, accession 0001493152-24-034208.Revenue: $5.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-08-28, accession 0001493152-24-034208.Report this figure11.3%Gross margin, FY2024, twelve months to 2024-05-31. gross profit / revenueGross profit: $611.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-08-29, accession 0001641172-25-026041.Revenue: $5.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-08-29, accession 0001641172-25-026041.Report this figure9.4%Gross margin, FY2025, twelve months to 2025-05-31. gross profit / revenueGross profit: $498.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-08-31, accession 0001493152-26-040851.Revenue: $5.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851.Report this figure8.1%Gross margin, FY2026, twelve months to 2026-05-31. gross profit / revenueGross profit: $362.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-08-31, accession 0001493152-26-040851.Revenue: $4.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851.Report this figure
Operating margin%(24.0%)Operating margin, FY2022, twelve months to 2022-05-31. operating income / revenueOperating income: −$4.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-08-25, accession 0001493152-23-030254.Revenue: $18.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-08-25, accession 0001493152-23-030254.Report this figure(135.3%)Operating margin, FY2023, twelve months to 2023-05-31. operating income / revenueOperating income: −$7.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-08-28, accession 0001493152-24-034208.Revenue: $5.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-08-28, accession 0001493152-24-034208.Report this figure(117.6%)Operating margin, FY2024, twelve months to 2024-05-31. operating income / revenueOperating income: −$6.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-08-29, accession 0001641172-25-026041.Revenue: $5.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-08-29, accession 0001641172-25-026041.Report this figure(96.7%)Operating margin, FY2025, twelve months to 2025-05-31. operating income / revenueOperating income: −$5.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-08-31, accession 0001493152-26-040851.Revenue: $5.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851.Report this figure(119.5%)Operating margin, FY2026, twelve months to 2026-05-31. operating income / revenueOperating income: −$5.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-08-31, accession 0001493152-26-040851.Revenue: $4.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851.Report this figure
Net margin%(24.0%)Net margin, FY2022, twelve months to 2022-05-31. net income / revenueNet income: −$4.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-08-25, accession 0001493152-23-030254.Revenue: $18.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-08-25, accession 0001493152-23-030254.Report this figure(133.7%)Net margin, FY2023, twelve months to 2023-05-31. net income / revenueNet income: −$7.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-08-28, accession 0001493152-24-034208.Revenue: $5.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-08-28, accession 0001493152-24-034208.Report this figure(110.4%)Net margin, FY2024, twelve months to 2024-05-31. net income / revenueNet income: −$6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-08-29, accession 0001641172-25-026041.Revenue: $5.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-08-29, accession 0001641172-25-026041.Report this figure(93.6%)Net margin, FY2025, twelve months to 2025-05-31. net income / revenueNet income: −$5.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-08-31, accession 0001493152-26-040851.Revenue: $5.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851.Report this figure(84.8%)Net margin, FY2026, twelve months to 2026-05-31. net income / revenueNet income: −$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-08-31, accession 0001493152-26-040851.Revenue: $4.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-08-31, accession 0001493152-26-040851.Report this figure
Diluted EPS$ per share(0.36)Diluted EPS, FY2022, twelve months to 2022-05-31−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-08-25, accession 0001493152-23-030254.Report this figure(0.50)Diluted EPS, FY2023, twelve months to 2023-05-31−$0.50 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-08-28, accession 0001493152-24-034208.Report this figure(2.84)Diluted EPS, FY2024, twelve months to 2024-05-31−$2.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-08-29, accession 0001641172-25-026041.Report this figure(2.16)Diluted EPS, FY2025, twelve months to 2025-05-31−$2.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-08-31, accession 0001493152-26-040851.Report this figure(1.30)Diluted EPS, FY2026, twelve months to 2026-05-31−$1.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-08-31, accession 0001493152-26-040851.Report this figure
Free cash flow$m(0.5)Free cash flow, FY2022, twelve months to 2022-05-31. operating cash flow − capital expenditureOperating cash flow: −$479.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-08-25, accession 0001493152-23-030254.Capital expenditure: $57.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-08-25, accession 0001493152-23-030254.Report this figure(5.5)Free cash flow, FY2023, twelve months to 2023-05-31. operating cash flow − capital expenditureOperating cash flow: −$5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-08-28, accession 0001493152-24-034208.Capital expenditure: $64.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-08-28, accession 0001493152-24-034208.Report this figure(5.4)Free cash flow, FY2024, twelve months to 2024-05-31. operating cash flow − capital expenditureOperating cash flow: −$5.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-08-29, accession 0001641172-25-026041.Capital expenditure: $51.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-08-29, accession 0001641172-25-026041.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Biomerica Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$42.9k24,347Reduced−31,695
BlackRock, Inc.2026-06-30$32.8k18,636Unchanged
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$25.5k14,514Unchanged
JANE STREET GROUP, LLC2026-06-30$22.2k12,640New+12,640
LPL Financial LLC2026-06-30$19.1k10,849Unchanged
UBS Group AG2026-06-30$12.2k6,951Added+6,432
VANGUARD FIDUCIARY TRUST CO2026-06-30$11.6k6,613Unchanged
NewEdge Advisors, LLC2026-06-30$6.3k3,603New+3,603
Tower Research Capital LLC (TRC)2026-06-30$419238New+238
HOLLENCREST CAPITAL MANAGEMENT2026-06-30$352200Reduced−625

Recent filings

All 427 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Biomerica Inc, recent filings
FiledFormWhat it isAccession number
2026-10-1621:00 ETDEF 14AProxy statementPeriod 2026-10-160001493152-26-047438
2026-10-1521:00 ET10-QQuarterly reportPeriod 2026-08-310001493152-26-047271
2026-10-1521:00 ET8-K5.02 Departure or appointment of officers or directors0001493152-26-047270
2026-09-2821:00 ET10-K/AAnnual report, amendedPeriod 2026-05-310001493152-26-044621
2026-08-3121:00 ET10-KAnnual reportPeriod 2026-05-310001493152-26-040851
2026-08-2821:20 ETSCHEDULE 13DOwnership report, active investor0001213900-26-095193
2026-08-2620:54 ET8-K1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits0001493152-26-040251
2026-06-0420:45 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001493152-26-027290
2026-04-1321:15 ET10-QQuarterly reportPeriod 2026-02-280001493152-26-016388
2026-01-1422:15 ET10-QQuarterly reportPeriod 2025-11-300001493152-26-002286

Latest annual report

Form 10-K for the fiscal year ended May 31, 2026Filed Aug 31, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
73290
Tickers
BMRA
Exchange
Nasdaq
SIC code
2835 In Vitro & In Vivo Diagnostic Substances
Sector
Healthcare
Fiscal year ends
May 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:20 ET. Listed shows no prices and gives no investment advice.